


The New Measure
of Confidence



HGT3

**HEIDELBERG
ENGINEERING**

THE NEW

HRT3


The most proven predictor of glaucoma.¹ Period.

Only one device is proven to predict glaucoma and detect damage caused by the disease years earlier than other technologies.¹ Only one device is proven to accurately track disease progression over time.²

If you want to confidently assess, diagnose and manage your glaucoma patients, there is only one device that measures up. The new HRT3 from Heidelberg Engineering.



Powerful + Portable



Assess


Proven by OHTS to Predict Glaucoma¹

The HRT is one of the top predictive factors for glaucoma.¹

In fact, the Ocular Hypertension Treatment Study (OHTS) has shown the HRT not only identifies those patients at high risk for developing glaucoma; it can also identify those at low risk with a greater than 90% accuracy at initial assessment.¹

- Optic disc assessment is the single most predictive factor in helping to detect glaucoma.³
- Preferred practice patterns from AAO, AOA and the AIGS consensus meeting all recommend documenting the optic disc as part of routine clinical examinations.

HRT Compared to the Top 5 Predictive Factors for Glaucoma¹





Diagnose

Proven by OHTS to Detect Damage Years Earlier¹


Most glaucoma cases are first diagnosed by optic disc assessment.⁴

In fact, OHTS has shown that HRT topographic measurements can detect structural damage up to 8 years earlier than expert assessment of stereo disc photography or visual field loss.¹

The HRT is the only imaging device proven by longitudinal studies to accurately measure all aspects of the optic disc: CUP, RIM, and RNFL.

- Largest normative database
- All parameters are adjusted for optic disc size
- Ethnic-selectable databases
- OU database with asymmetry analysis

OHTS results show that without optic disc assessment you may be missing up to 55% of glaucoma patients.



How Glaucoma Is Detected⁴

Manage


Proven by 10-Year Follow-Up to Accurately Measure Progression⁵

You can't call it progression until you do the math.


To confidently manage the ongoing treatment of your glaucoma patients, you need to accurately track and measure the progression of their disease. Unlike other technologies that rely on simple comparison, the HRT applies statistical analysis that can help differentiate true biological change from random variability.

- Utilizes statistical progression—not simple serial comparison
- Tracks area and volume changes

Is This Change Significant?



This Change Is Significant.




The HRT 3 – An Expandable Platform

In addition to being the industry's most powerful tool for the detection and management of glaucoma, the HRT 3 can be expanded to include retina edema or cornea analysis.

Retina Edema Module

The HRT3 retina option provides 3-D images of retinal pathology and unique edema maps that can help to locate and quantify macular edema.

- Aids early detection of diabetic macular edema
- 9-zone analysis based on ETDRS
- Identifies, maps, and quantifies edema
- Monitors edema over time



Diabetic Macular Edema

Rostock Cornea Module

The Rostock Cornea Module adds confocal scanning microscopy to the HRT 3, allowing for the acquisition of high-resolution images of corneal cell structures with 1 μm resolution.

- Layer-by-layer corneal imaging from epithelium to endothelium
- LASIK and PIOL pre- and post-surgical assessment
- Assessment of corneal dystrophies
- Monitoring of long-term contact lens wearers



Langerhans Cells

1. Zangwill LM, Weinreb RN, Beiser JA, et al. Baseline topographic optic disc measurements are associated with the development of primary open angle glaucoma: the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. *Arch Ophthalmol.* 2005;123.
2. Chauhan BC, McCormick TA, Nicoleta MT, LeBlanc RP. Optic disc and visual field changes in a prospective longitudinal study of patients with glaucoma: comparison of scanning laser tomography with conventional perimetry and optic disc photography. *Arch Ophthalmol.* 2001;119:1492-1499.
3. Bengtsson B, Heijl A. A long-term prospective study of risk factors for glaucomatous visual field loss in patients with ocular hypertension. *J Glaucoma.* 2005;14:135-138.
4. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Arch Ophthalmol.* 2002;120: 701-713.
5. Data on file. Heidelberg Engineering GmbH.



Decision Checklist

New technology can be a benefit or a burden to your practice. Review this checklist to see how well other technologies compare to the benefits of the HRT3.

- | HRT3 | Others | |
|-------------------------------------|--------------------------|---|
| | | Glaucoma Management |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | OHTS data demonstrating predictive value in glaucoma |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Progression analysis based on statistics, not simplified serial displays |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Parameters adjusted for optic disc size |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | 10-year follow-up data |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Ethnic-selectable databases |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Supporting data meeting evidence-based medicine standards |
| | | Versatility |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Glaucoma, retina, and cornea applications |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Backward-compatible data to minimize obsolescence |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Able to add applications at a later time |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Broad product offering to match practice needs |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Portability |
| | | Cost of Ownership |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Low cost of ownership (warranty and maintenance) |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Service by mail minimizes practice downtime |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Comprehensive Web support |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Staff training courses |
| | | Global Acceptance |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | No studies showing significant artifact |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | The most frequently used imaging technology by attendees of the World Glaucoma Congress |

For more information on the HRT3, call 800 931-2230 or visit www.HeidelbergEngineering.com



Corporate Headquarters

Heidelberg Engineering GmbH • Gerhart-Hauptmann-Strasse 30 • 69221 Dossenheim • Germany
Phone +49-62 21-64 63 0 • Fax +49-62 21-64 63 62 • www.HeidelbergEngineering.de

U.S.A.

Heidelberg Engineering, Inc. • 1499 Poinsettia Avenue, Suite 160 • Vista, CA 92081
Phone 760 598-3770 • Fax 760 598-3060 • www.HeidelbergEngineering.com